EUSA Finds Japanese Partner For Lead Product In Generics-turned-innovator Ohara
This article was originally published in PharmAsia News
Executive Summary
TOKYO - In-licensing firm EUSA Pharma established its first partnership in Japan, behind similar deals in South Korea and China, for its acute lymphoblastic leukemia treatment Erwinase (erwinia L-asparaginase)
You may also be interested in...
EUSA Wins U.S. Approval of Erwinaze; Shipping To Start Week Of Nov. 20
Eusa hopes the approval will help cement its efforts in the U.S., where it has been trying to build a strong presence for several years.
Novamed In-Licenses Products from Iroko and EUSA To Strengthen Cardiovascular And Oncology Pipeline
SHANGHAI - NovaMed Pharmaceuticals announced July 10 it has reached agreements with U.S.-based Iroko and U.K. firm EUSA Pharma to in-license Iroko's cardiovascular drugAggrastat (tirofiban) and EUSA's oncology drug Erwinase (crisantaspase)
EUSA Pharma Gains Foothold In U.S. Market With Cytogen Acquisition
Buyout positions U.K. drug maker to take on new licensing deals on both sides of the Atlantic; oncology filing planned within 12 months, EUSA tells the DAILY.